Adalimumab induces deep remission in patients with Crohn's disease
Abstract
In an exploratory study of patients with moderate to severe ileocolonic CD who received adalimumab induction and maintenance therapy, patients achieving deep remission appeared to have better 1-year outcomes than those not achieving deep remission. These findings should be validated in large, prospe …
Keywords
National Center for Biotechnology Information
NCBI
NLM
MEDLINE
humans
pubmed abstract
nih
national institutes of health
national library of medicine
treatment outcome
research support
non-u.s. gov't
adult
female
male
middle aged
Remission Induction
Randomized Controlled Trial
Antibodies
Monoclonal
Humanized / therapeutic use*
anti-inflammatory agents / therapeutic use*
crohn disease / drug therapy*
placebos / administration & dosage
jean-frédéric colombel
adalimumab
crohn disease / pathology
pmid:23856361
doi:10.1016/j.cgh.2013.06.019
paul j rutgeerts
jingdong chao
Access
Citation
ID:
268728
References
Blockchain Verification
Account:
NFT Contract Address:
0x95644003c57E6F55A65596E3D9Eac6813e3566dA
Article ID:
268728
Unique Identifier:
Network:
Scimatic Chain (ID: 481)
Loading...
Blockchain Readiness Checklist
Authors
Abstract
Journal Name
Year
Title
Creates 1,000,000 NFT tokens for this article
Token Features:
- ERC-1155 Standard NFT
- 1 Million Supply per Article
- Transferable via MetaMask
- Permanent Blockchain Record
Scan with Saymatik Web3.0 Wallet